Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Carcinoma, Renal Cell 11Prostatic Neoplasms 2Neoplasm Metastasis 2Vulvar Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Gallbladder Neoplasms 1Disease Progression 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Trastuzumab 3pembrolizumab 2Paclitaxel 2Nivolumab 2Interleukin-12 Subunit p35 2Docetaxel 2Cisplatin 2Carboplatin 2trastuzumab deruxtecan 1tivozanib 1tipifarnib 1seribantumab 1sargramostim 1pertuzumab 1lenvatinib 1entinostat 1atezolizumab 1Thalidomide 1Specimen Handling 1Psychiatric Rehabilitation 1Peripheral Blood Stem Cell Transplantation 1Oxaliplatin 1Mesna 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Interleukin-12 1Immunohistochemistry 1Ifosfamide 1Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gallbladder Neoplasms × tivozanib × Genitourinary × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡